Top Suppliers:I want be here


299-75-2

299-75-2 structure
299-75-2 structure

Name (2S,3S)-Threitol 1,4-bismethanesulfonate
Synonyms Tresulfan
L-threitol 1,4-bismethane sulfonate
Dihydroxymyleran
L-Dihydroxy-Busulfan
1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate
2,3-dihydroxybutane-1,4-diyl dimethanesulfonate
Dihydroxybusulfan
Treosulfan
Treosulphan
THREOSULFAN
CB-2562
2,3-Dihydroxy-1,4-butanediyl dimethanesulfonate
Description Treosulfan (NSC 39069;Treosulphan) is an alkylating agent with activity in ovarian cancer and other solid tumor types.
Related Catalog
Target

DNA Alkylator[1]

In Vitro Treosulfan is an alkylating agent. Treosulfan inhibits several cancer cell lines, such as Panc-1, Miapaca-2 and Capan-2 cells, with IC50s of 3.6 μg/mL, 1.8 μg/mL and 2.1 μg/mL respectively, and shows nearly 100% cytotoxicity on these cell lines at 100 μg/mL. Treosulfan (0.1-100 μg/mL) in combination with gemcitabine exhibits enhanced activity against cancer cells. However, Treosulfan (1, 2.5, 5 μg/ml) combined with 5-fluorouracil (5-FU; 0.1, 0.25, 0.5 μg/ml) has antagonistic effect on Panc-1 cells at intermediate and high concentrations, and on Miapaca-2 cells at all doses[1]. Treosulfan (800 µg/mL) dramatically reduces erythrocyte forward scatter, increases the percentage of annexin-V-binding cells, [Ca2+]i, and ROS. Removal of extracellular Ca2+ abrogates the effect of Treosulfan on annexin-V-binding[2].
In Vivo Treosulfan (1.5 g/kg/day) induces a rapid myeloablation, depletes the splenic B and T cells in mice. Treosulfan (1.5 g/kg/day) causes olny interleukin-2 production in spleen cells for a short time and without obvious significant effect on synthesis of tumor necrosis factor-α and/or interferon-γ in mice[3].
Cell Assay For cytotoxicity assays, the cells are plated at 1×104 cells/mL grown in 100 μL volume per well of 96-well tissue culture plates. The cells are left to adhere overnight and thereafter incubated with different concentrations of Treosulfan alone or in combination with gemcitabine. The drug combination is added to the cell cultures simultaneously or sequentially (the second drug added 12 h after the first). After 72 h of incubation, Alamar Blue® solution is added to the wells prior to further overnight incubation. Absorbance is then measured on a spectrophotometer and cell proliferation and cytotoxicity of drugs are calculated. In some experiments, proliferation and cytotoxicity are also determined by using trypan blue exclusion and cell counting with an improved Neubauer hemocytometer and cell viability assessed by staining the cells with 7-amino-actinomycin D (final concentration 200 μg/mL) and Annexin-V and analyzing via flow cytometry using a FACS Scan flow cytometer[1].
Animal Admin Mice[3] Female BALB/c mice are 10 to 12 weeks old and weighed approximately 20 g. Animals are fed with standard pelleted food and water ad libitum. They are housed in a climatized chamber with a dark/light cycle of 12 hours. They are divided into four groups: one group is given Treosulfan (1.5 g/kg/day) for 3 consecutive days, one group receives cyclophosphamide (0.1 g/kg/day) for 2 consecutive days, one group is treated with liposomal busulfan (37 mg/kg/day) for 4 consecutive days, and there is a control group with no treatment. Cyclophosphamide, busulfan, and Treosulfan doses are given at sublethal doses to maintain survival of the animals without bone marrow support. Animals are sacrificed on days 1, 3, 6, 9, and 12, after the last dose of treatment, and the spleen and femurs are removed. Six animals are included in each time point for the treated animals and two control animals[3].
References

[1]. Nitsch E, et al. Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. Anticancer Res. 2014 Apr;34(4):1779-84.

[2]. Peter T, et al. Programmed erythrocyte death following in vitro Treosulfan treatment. Cell Physiol Biochem. 2015;35(4):1372-80.

[3]. Sjöö F, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 2006 Jan;34(1):115-21.

Density 1.6±0.1 g/cm3
Boiling Point 607.0±55.0 °C at 760 mmHg
Molecular Formula C6H14O8S2
Molecular Weight 278.301
Flash Point 320.9±31.5 °C
Exact Mass 278.013000
PSA 143.96000
LogP -1.64
Vapour Pressure 0.0±3.9 mmHg at 25°C
Index of Refraction 1.518
Storage condition 2-8℃

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XO8500000
CHEMICAL NAME :
L-Threitol, 1,4-bismethanesulfonate
CAS REGISTRY NUMBER :
299-75-2
LAST UPDATED :
199707
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C6-H14-O8-S2
MOLECULAR WEIGHT :
278.32
WISWESSER LINE NOTATION :
WS1&O1YQYQ1OSW1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
222 mg/kg
TOXIC EFFECTS :
Gastrointestinal - other changes Blood - leukopenia Blood - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
222 mg/kg
TOXIC EFFECTS :
Blood - leukopenia Blood - agranulocytosis Blood - other changes
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Micronucleus test

MUTATION DATA

TYPE OF TEST :
Mutation in mammalian somatic cells
TEST SYSTEM :
Rodent - hamster Ovary
DOSE/DURATION :
100 umol/L
REFERENCE :
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 21,95,1993 *** REVIEWS *** IARC Cancer Review:Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,341,1981 IARC Cancer Review:Animal No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,341,1981 IARC Cancer Review:Group 1 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,363,1987
RIDADR UN 2811
Packaging Group III
Hazard Class 6.1(b)